E16.3

Increased secretion of glucagon

Billable FY2026 2025-10-01 → 2026-09-30

Exclusions 1 never code together

Excludes1

transitory endocrine and metabolic disorders specific to newborn (P70-P74)P70-P74

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Instructional notes 2

Inclusion terms

Notes

All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.E05.8 E07.0 E16-E31 E34.-

Index entries leading here 5

Abnormal, abnormality, abnormalities — see also Anomaly
- glucagon secretion E16.3
- secretion
  - glucagon E16.3
Hyperplasia, hyperplastic
- pancreatic islet cells E16.9
  - alpha E16.8
    - with excess
      - glucagon E16.3
Excess, excessive, excessively
- glucagon E16.3
Hypersecretion
- glucagon E16.3
Increase, increased
- secretion
  - glucagon E16.3

Alongside this code 7 same parent — E16

Additional references

AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Present FY2024–FY2027.